Clinical Trial

A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B

Study acronym: HBV
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 15, 2026 (before its estimated June 7, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of BW-20507 in combination with PEG-IFNα in CHB patients
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-18; most recent amendment 2026-01-14.
Status change: Recruiting → Active, Not Recruiting 2026-01-14
Status change: Not Yet Recruiting → Recruiting 2025-11-19
Trial Details
NCT Number NCT07135349
Lead Sponsor Shanghai Argo Biopharmaceutical Co., Ltd.
Conditions Chronic Hepatitis B
Enrollment 209 participants
Start Date 2025-09-02
Primary Completion 2026-06-07 (estimated)
Study Completion 2028-05-08 (estimated)
Updated on ClinicalTrials.gov 2026-01-15